Claimed effect · Tirzepatide

Does Tirzepatide help with cardiovascular events?

B
Grade B — probable, not settled1 outcomes RCT (2025) · effect size: small
Short answerProbable, not settled. Human data exist (1 outcomes RCT (2025)) and mostly agree, showing a small effect — but too few, too small, or not yet peer-reviewed for a firm answer. SURPASS-CVOT reported tirzepatide non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes; superiority over an active GLP-1 comparator was not shown.

What the studies show

SURPASS-CVOT reported tirzepatide non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes; superiority over an active GLP-1 comparator was not shown.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Eli Lilly. SURPASS-CVOT topline: tirzepatide vs dulaglutide on cardiovascular outcomes in type 2 diabetes.Press release, 2025; full publication pending at time of reviewNon-inferiority met; graded B until peer-reviewed.

In context

Tirzepatide is a once-weekly peptide that activates both GIP and GLP-1 receptors. It is approved for type 2 diabetes, weight management and obstructive sleep apnoea, and in the only direct head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with a similar side-effect profile. It is a prescription medicine; versions sold outside that channel are unlicensed.

Tirzepatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tirzepatide proven to help with cardiovascular events?
Not yet settled. 1 outcomes RCT (2025) — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
SURPASS-CVOT reported tirzepatide non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes; superiority over an active GLP-1 comparator was not shown.
Is Tirzepatide approved for this?
Tirzepatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tirzepatide

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →